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Background: Diabetes mellitus (DM) is a common secondary cause of dyslipidaemia, particularly if glycaemic control is poor, 
which in turn is an important risk factor for atherosclerosis and coronary artery disease.
Objectives: (1) To study the prevalence and pattern of dyslipidaemia in patients with type 2 DM. (2) To determine the relationship 
(if any) between HbA1C and the lipid profile in type 2 diabetic patients.
Methods: This was a cross-sectional study done in 200 type 2 diabetic patients attending the Diabetic Clinic at the Helen Joseph 
Hospital. Patients suffering from other known causes of secondary dyslipidaemia were excluded. Each patient’s HbA1C and lipid 
profile results were recorded from their clinic files. The lipid profile included total cholesterol (TC), triglyceride (TG), high-density 
lipoprotein cholesterol (HDL-C) and calculated low-density lipoprotein cholesterol (LDL-C).
Patients with one or more of the above parameters outside the targets recommended by the 2012 South African Dyslipidaemia 
Guidelines were considered to have uncontrolled dyslipidaemia.
Results: Of the 200 type 2 DM patients studied, 86 (43%) were male and 114 (57%) female.
Despite all patients being treated with lipid-lowering therapy (simvastatin at a mean daily dose of 20 mg), 187 patients (93.5%) 
did not achieve all their lipid targets. The most prevalent lipid parameter not at target was an LDL-C of ≥ 1.8 mmol/l in nearly 
80% of patients. The most common pattern of dyslipidaemia was a combined dyslipidaemia (any two abnormal lipid parameters) 
affecting a total of 82 out of the 187 patients (43.8%) not reaching recommended targets. No significant relationship was found 
between HbA1C and any of the lipid parameters.
Conclusion: The vast majority of the type 2 diabetic patients studied had dyslipidaemia not meeting recommended targets, 
despite the use of lipid-lowering therapy in all patients. There is a need for more intensive lipid-lowering therapy, particularly 
statin therapy in patients with dyslipidaemia. Measures aimed at combating obesity and other lifestyle-related risk factors are 
also vital and need to be implemented for effectively controlling dyslipidaemia and reducing the burden of CVD.
Keywords: combined dyslipidaemia, LDL, lipid targets
Introduction
Type 2 diabetes mellitus (DM) is a metabolic disorder, 
characterised by hyperglycaemia resulting from defects in 
insulin secretion, insulin action, or both.1
The International Diabetes Federation has estimated that the 
number of people with diabetes worldwide in 2015 was 415 
million and this is projected to reach 642 million by 2040.2 In 
2015 diabetes was the leading cause of mortality, whereby 5 
million people died from diabetes and diabetes-related 
complications.2 The long-term macrovascular complications of 
diabetes contribute to the high morbidity and mortality 
associated with the disease with as many as 80% dying from 
some form of cardiovascular disease (CVD).3
Well-known risk factors for CVD include age, gender, hypertension 
(HT) and DM. Other lifestyle behaviours such as tobacco smoking, 
excessive alcohol consumption, sedentary lifestyle and poor diet 
with resultant obesity further contribute to elevating one’s CVD risk.
Diabetic patients often suffer from HT and also have abnormal 
lipoprotein metabolism.1,4 Dyslipidaemia is one of the major risk 
factors for CVD in DM. The most common pattern of dyslipidaemia 
is hypertriglyceridaemia and reduced HDL cholesterol levels and 
an increased concentration of small dense low-density 
lipoprotein (LDL) particles. The precise pathogenesis of diabetic 
dyslipidaemia is not known; however, a large body of evidence 
suggests that insulin resistance has a central role in the 
development of this condition. The main cause of the lipid 
changes associated with DM is attributed to increased free fatty 
acid flux secondary to insulin resistance.1,4
Bearing this in mind, it should be the clinician’s aim to control 
hyperglycaemia and HT as well as dyslipidaemia with lifestyle 
measures and/or medication to try and reduce their CVD risk. As 
macrovascular disease is the major cause of mortality in diabetic 
patients, blood pressure and lipid targets are set lower for this 
high-risk group than in the general population.
Apart from the classical risk factors such as dyslipidaemia, 
elevated HbA1C is regarded as an independent risk factor for CVD 
in subjects with or without diabetes. The estimated risk of CVD 
has shown to be increased by 18% for each 1% increase in 
absolute HbA1C value in the diabetic population.
5
In clinical practice, it was previously advocated to use fasting lipid 
profiles. However, solid evidence is lacking that fasting samples 
are superior to non-fasting samples when evaluating a patient’s 
lipid profile for his/her cardiovascular risk assessment. Bearing this 
in mind other countries have changed their recommendations to 
using random non-fasting lipid profiles as the standard, i.e. 
Denmark6 and UK NICE guidelines.7 This has advantages as it is 
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more convenient for the patient, which will hopefully ease the 
patient’s hospital visits and ensure better compliance.8
The aim of statin therapy is to lower LDL-C levels. Statin therapy 
is used extensively in both primary and secondary prevention of 
CVD at all levels of healthcare settings.9–11 Several large 
prospective clinical trials have shown that for every 1  mmol/l 
reduction in LDL-C levels there is a 23% reduction in CVD risk.12–15 
In a further meta-analysis of studies comparing high and low 
statin doses, more intensive lowering of LDL-C (0.51  mmol/l 
additional reduction) in the high-dose statin arm was associated 
with a further 15% reduction in CVD risk.16 In the JUPITER study, 
a statin cardiovascular outcomes trial that enrolled men and 
women free of overt CVD over the ages of 50 and 60  years 
respectively with baseline LDL-C  <  3.37  mmol/l and high-
sensitivity C-reactive protein of 2  mg/l or greater; who were 
randomised to rosuvastatin 20  mg/day or placebo statin 
treatment was associated with a 39% reduction in primary 
endpoints (myocardial infarction, stroke, admission to hospital 
for unstable angina, arterial revascularisation or CV death) in 
patients with at least one risk factor for DM.17,23
The results of these and other studies have given rise to treatment 
guidelines recommending lower LDL-C target levels.18,19,23 Thus far 
many studies, local and international, have failed to demonstrate 
that patients reach these recommended targets.20–23
The aim was to determine the prevalence and pattern of 
dyslipidaemia in type 2 DM patients and to determine how 
dyslipidaemia is being managed in patients with type 2 DM in a 
South African, public sector, tertiary care setting and, second, to 
determine the relationship (if any) between HbA1C and the lipid 
parameters.
Materials and methods
Ethics approval was obtained from the Human Research Ethics 
Committee, University of the Witwatersrand, Johannesburg 
(protocol number: M120536). This cross-sectional study 
evaluated 200 type 2 diabetic patients attending the Diabetic 
Clinic at the Helen Joseph Hospital during July and August 2012. 
Patients were excluded from the study if they were  <  18  years 
of age, had Type 1 diabetes mellitus, gestational diabetes, 
steroid-induced diabetes or chronic pancreatitis as a secondary 
cause of DM. Patients suffering from other causes of 
secondary dyslipidaemia such as overt hypothyroidism were 
also excluded.
Using patients’ clinic files, the following clinical data were 
recorded: gender, age, duration of DM, smoking status, height, 
weight (BMI), HbA1C, lipid profile, concomitant HT and medication 
pertaining to the management of their HT, DM and dyslipidaemia. 
The lipid profile included total cholesterol (TC), triglyceride (TG), 
high-density lipoprotein cholesterol (HDL-C) and calculated 
low-density lipoprotein cholesterol (LDL-C). Lipid profiles were 
non-fasting, which is in keeping with recent recommendations 
from the European Society of Cardiology.5
LDL-C is preferred when deciding on whether to treat a patient 
and for subsequent assessments, as cardiovascular risk reduction 
is proportional to LDL-C level. However, LDL-C cannot be 
calculated using the Friedewald equation if the triglyceride level 
is ≥ 4.5 mmol/l and would need to be measured either directly or 
by means of ultracentrifugation.
According to the 2012 South African Dyslipidaemia Guidelines,24 
target levels in patients with type 2 diabetes are:
TC < 4.5 mmol/l;
TG < 1.7 mmol/l;
HDL-C > 1.0 mmol/l in men and > 1.2 mmol/l in women;
LDL-C < 1.8 mmol/l.
With the above targets in mind, dyslipidaemia was defined by 
the presence of one or more abnormal serum lipid concentration 
outside these recommended target levels.
BMI was defined as the weight in kilograms divided by the height 
in metres squared expressed as kg/m2. Patients were classified as: 
underweight (BMI  <  20  kg/m2), normal (BMI 20–24.9  kg/m2), 
overweight (BMI > 25–29.9 kg/m2) or obese (BMI > 30 kg/m2).
The 2012 SEMDSA guidelines25 recommend a target HbA1C of less 
than 7% for the majority of patients because they prevent or 
significantly delay complications of DM. Good glycaemic control 
was defined as an HbA1C level of  <  7% and was considered 
uncontrolled if  ≥  7%. Those subjects with dyslipidaemia were 
further classified into mixed dyslipidaemia (three abnormal 
parameters: high TG, low HDL-C as well as raised LDL-C), 
combined dyslipidaemia (any two abnormal lipid parameters) 
and isolated (single parameter) dyslipidaemia (high TC, TG, LDL-C 
or low HDL-C). A comparison was also made of the lipid levels in 
patients with good control of diabetes (HbA1C<7%) versus those 
with poorer glycaemic control (HbA1C ≥ 7%). A multiple regression 
was done in order to determine whether HbA1C correlated with 
any of the lipid parameters, namely TC, TG, HDL-C and/or LDL-C.
A p-value  <  0.05 was considered significant. The descriptive 
analysis of the data was done using statistical software SPSS 19.0™ 
(IBM Corp, Armonk NY, USA). Graphs and tables were generated 
using Microsoft Word and Excel (Microsoft Corp, Redmond, USA).
Results
In the sample group of 200 type 2 DM patients, 43% were males 
and 57% females. The mean age of the sample was 55.89 years 
(SD ± 12.52). The earliest age of being diagnosed with DM was 18 
years and the oldest age 72 years. The mean age of diagnosis was 
42.19 years (SD ± 10.74). The demographics of the study cohort 
are shown in Table 1.
Dyslipidaemia
Despite the use of lipid-lowering therapy (statin therapy) in all of 
the patients, the prevalence of dyslipidaemia in the cohort was 
93.5% (187 out of the 200 patients).
Simvastatin was the only statin therapy used by all patients. The 
mean dose of simvastatin was 20 mg.
No documentation of any complications from the statin therapy 
was noted in the files. Compliance was not assessed.
The most prevalent lipid abnormality in our study was LDL-C 
of  ≥  1.8  mmol/l (81.8%) in nearly 80% of both the male and 
female patients (Table 2).
The most common pattern of dyslipidaemia was a combined 
dyslipidaemia (any two abnormal lipid parameters) in a total of 
82 of the 187 patients (43.8%) not achieving recommended 
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years and the oldest age 72 years. The mean age of diagnosis was 
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are shown in Table 1.
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93.5% (187 out of the 200 patients).
Simvastatin was the only statin therapy used by all patients. The 
mean dose of simvastatin was 20 mg.
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targets (see Table 3). The most common pattern of combined 
dyslipidaemia in males was low HDL-C levels (≤ 1 mmol/l) and 
elevated LDL-C levels (≥ 1.8 mmol/l) (23.25%) and in females was 
an elevated TG (≥ 1.7 mmol/l) in combination with an elevated 
LDL-C level (19.29%) (Figures 1 and 2, respectively).
HbA1C
The mean HbA1C in this study was 9.5% (SD 2.4); range 4.5–
17.6%). The majority of the patients, 173 out of 200 (86.5%), had 
poor glycaemic control with an HbA1C of ≥ 7%. Only 28 patients 
(14.0%) had a target HbA1C of  <  7%. The majority of patients 
(40%) had HbA1C levels > 10%.
Of these 173 patients with an HbA1C of ≥ 7, 49.7%, 43.9%, 46.2% 
and 76.3% had TC, TG, HDL-C, and LDL-C levels outside the 
recommended levels respectively. In those with good glycaemic 
control (HbA1C of < 7%) 28%, 32%, 48% and 80% of patients had 
TC, TG, HDL-C, and LDL-C levels outside the recommended levels 
respectively.
Table 1: Profile of the patients analysed
Parameter Results





Mean ±SD 55.89 ± 12.52
Median 58
Range 30–82
Male, mean ±SD 53.29 ± 12.73
Female, mean ±SD 57.85 ± 12.04
Age at diagnosis (years) Results
Mean ±SD (years) 42.19 ± 10.74
Median 40
Range 18–72
Male, mean ±SD 41.34 ± 10.81
Female, mean ±SD 42.82 ± 10.69
No. of Insulin units used perday Results






No insulin use 1 (0.5%)
BMI Results
Underweight (BMI < 20 kg/m2) 5 (2.5%)
Normal (BMI 20 to 24.9 kg/m2) 31 (15.5%)
Overweight (BMI > 25 to 29.9 kg/m2) 41 (20.5%)
Obese (BMI > 30 kg/m2) 123 (61.5%)
Table 2: Breakdown of dyslipidaemia in males and females








% not at 
target
TC ≥4.5 mmol/l 5.30 ±0.77 37.21% 5.63 ±0.90 54.39%
TG ≥1.7 mmol/l 2.77 ±1.07 39.53% 2.83 ±1.24 43.86%
HDL ≤1 mmol/l (M) 
< 1.2 mmol/l (F)
0.9 ±0.12 55.81% 1.11 ±0.87 38.60%
LDL ≥1.8 mmol/l 2.69 ±0.74 76.74% 2.97 ±0.86 76.32%
Table 3: Breakdown of the pattern of dyslipidaemia in the 187 patients 
not achieving recommended lipid targets
*Dyslipidaemia was classified into mixed dyslipidaemia (three abnormal 
parameters: high TG, low HDL-C as well as raised LDL-C), combined 
dyslipidaemia (any two abnormal parameters) and isolated (single 
parameter) dyslipidaemia (TC, TG, HDL-C or LDL-C).
Type* Males (n = 81) Females (n = 106) Total (n = 187)
Isolated 28 47 75 (40%)
Combined 39 43 82 (43.8%)
Mixed 14 16 30 (16%)
Figure 1: shows the percentage breakdown of dyslipidaemia in the 
male cohort (n = 86), using the 2012 South African Dyslipidaemia 
Guidelines, target levels.
Figure 2: shows the percentage breakdown of dyslipidaemia in the 
female cohort (n=114), using the 2012 South African Dyslipidaemia 
Guidelines, target levels.
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be taken as outlined by the 2012 SEMDSA guidelines. It was not 
the objective of this study to determine factors relating to the 
elevated HbA1C levels but this again highlights the need for 
better emphasis on glycaemic control. However, no significant 
relationship was found between HbA1C and serum lipid 
parameters.
A limitation of the study is that the cohort represented a small 
group of patients, with overall poor glycaemic control. Another 
limitation is that it was a non-random sample, conducted at a 
specialist diabetic clinic. Ethnicity, compliance with therapy and 
any possible side effects were not evaluated. Compliance and 
side effects of statin therapy were also not assessed.
Nonetheless, the results indicate disappointing achievement of 
targets, particularly lipid targets in state patients with type 2 DM.
The goal of achieving recommended targets remains elusive, 
given diminishing resources (healthcare workers, phar-
macotherapy etc.) and limited physician–patient interaction in 
the state sector. Improvement can only be achieved by more 
intensive statin therapy and ongoing patient education.
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A multiple regression was done in order to determine whether 
HbA1C correlated with any of the lipid parameters, namely TC, TG, 
HDL-C and/or LDL-C. None of these parameters correlated 




Despite the use of lipid-lowering therapy (statin therapy) in all of 
the patients, the prevalence of dyslipidaemia in the cohort was 
very high. This is in accordance with similar studies done in South 
Africa26 and Nigeria27 where the prevalence of dyslipidaemia (at 
least one abnormal lipid profile) was 90.3% and 90.7% 
respectively. Comparable findings were observed in international 
studies. In an Italian study, in which 2 465 patients were recruited, 
only 5% achieved the recommended goals for LDL-cholesterol, 
blood pressure, HbA1C and smoking habits.
28 Similarly, a Czech 
study concluded that only 1% of their patients achieved their 
goals, while 6% of the total cohort that consisted of 975 patients 
in a Norwegian study met the goal for the combined target of 
glucose, blood pressure and cholesterol control.29,30
This brings to light that controlling diabetes and dyslipidaemia is 
a global challenge affecting developed and developing countries 
alike. More resources (monetary, skill, therapeutics) need to be 
dedicated to trying to achieve better control in our patients.
The reasons for the high prevalence of dyslipidaemia in the 
cohort could be multifactorial.
It may be partly attributed to the current trend toward 
urbanisation and adoption of a Western diet and lifestyle, which 
results in a higher incidence of type 2 DM with its attendant 
metabolic abnormalities.
The statin used in the study was a less potent statin, simvastatin, 
at a suboptimal mean dose of only 20 mg daily. This inertia on 
the part of clinicians to increase the dose of a given medication 
or move to combination lipid-modifying treatment is not unique 
to South Africa, as shown in the DYSIS Study.23,31
In the state sector only simvastatin is routinely available for 
patients with dyslipidaemia. Other more potent statins such as 
atorvastatin are available on an individual motivational basis for 
patients with severe primary dyslipidaemia such as familial 
hypercholesterolaemia or who have established atherosclerotic 
cardiovascular disease. In addition state pharmacies often have a 
short supply of stock, leaving patients without any statin therapy 
until the next batch of stock arrives. Whilst not assessed in this 
study, compliance with therapy is another potential reason for 
patients not meeting recommended lipid targets.
In the state sector staff shortage is also a problem, resulting in 
higher volume load and hence shorter consultation times, which 
is then manifested in patients’ glycaemic, blood pressure and 
lipid targets not being achieved. This highlights the shortfalls 
experienced in the South African health system. Whilst this needs 
to be addressed with the appropriate powers, we as individuals 
can improve care to our patients by trying to adhere to current 
guidelines, and optimising patient care in terms of statin dose 
and dietary changes in order to achieve target levels.
Similar to previous local studies where patients had an out-of-
target HbA1C of 8.8%,
32 this study also found that the majority of 
the type 2 diabetics were poorly controlled. Many of the patients 
had HbA1C levels > 10%, which would require additional action to 
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Nonetheless, the results indicate disappointing achievement of 
targets, particularly lipid targets in state patients with type 2 DM.
The goal of achieving recommended targets remains elusive, 
given diminishing resources (healthcare workers, phar-
macotherapy etc.) and limited physician–patient interaction in 
the state sector. Improvement can only be achieved by more 
intensive statin therapy and ongoing patient education.
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